Parkinson's Blog

Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) — CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,

A son and a group of car enthusiasts came together to put on a surprise car show as a very special Father’s Day gift.

npj Parkinson’s Disease – Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates

Alexandra Noad LOCAL JOURNALISM INITIATIVE REPORTER A local man is teaching boxing to people with Parkinson’s disease to help improve their quality of

A group of friends from Newport are aiming to complete the Wales Coastal Path before they turn 70.

Scientific Reports – Detection of Parkinson disease using multiclass machine learning approach

npj Parkinson’s Disease – Subthalamic nucleus input-output dynamics are correlated with Parkinson’s burden and treatment efficacy

The market for neurological devices was valued at $12.5 billion in 2023 and is expected to grow by a CAGR of 4.60 per cent to reach $20.9 billion in 2033

Rams tight end Colby Parkinson talks about what it’s been like being closer to his family back home in Los Angeles over the past couple of months.

We are pleased to announce that Mike Ashton will step into the role of chair of our board of trustees. Mike joined the board towards the end of 2023,